

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/836,561	04/16/2001	Olga Bandman	PF-0333-2 DIV	PF-0333-2 DIV 8070	
;	7590 02/10/2003				
Legal Department			EXAMINER		
Incyte Genomics Inc 3160 Porter Drive			HUFF, SHEEL	A JITENDRA	
Palo Alto, CA	94304		ART UNIT	PAPER NUMBER	
			1642	12	
			DATE MAILED: 02/10/2003	DATE MAILED: 02/10/2003 /3	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		•				
		09/836,561	BANDMAN ET AL.			
	omee Acaem Cammary	Examiner	Art Unit			
	The MAII ING DATE of this communication ann	Sheela J Huff	1642			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status						
1)🖾	Responsive to communication(s) filed on $\underline{16D}$	<u>lecember 2002</u> .				
2a)⊠	This action is <b>FINAL</b> . 2b) This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
	on of Claims					
•	☐ Claim(s) 41-66 is/are pending in the application.					
	4a) Of the above claim(s) <u>43,44 and 47-66</u> is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
_	6)⊠ Claim(s) <u>41 and 45</u> is/are rejected.					
	7)⊠ Claim(s) <u>42 and 46</u> is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.  Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)□ T	he proposed drawing correction filed on					
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
:	2. Certified copies of the priority documents have been received in Application No					
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
<ul> <li>a) The translation of the foreign language provisional application has been received.</li> <li>15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>						
Attachment(s)						
2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)			

Application/Control Number: 09/836,561

Art Unit: 1642

**DETAILED ACTION** 

### Response to Amendment

The amendment filed on 12/16/02 has been considered. Applicant's arguments are deemed to be persuasive-in-part.

Claims 41-66 are pending.

Claims 43-44, 47-66 are withdrawn from consideration.

Claims 41-42 and 45-46 are currently under consideration.

Applicant's request for rejoinder has been noted and rejoinder will be considered at the appropriate time.

The rejection under 35 U.S.C. 112, first paragraph, written description is withdrawn in view of applicant's amendments.

# Response to Arguments Claim Rejections - 35 USC § 112

Claims 41 and 45 remain rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for SEQ Id No. 1 and biologically active fragments thereof, does not reasonably provide enablement for immunogenic fragments. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The reasons for this rejection are of record in paper no. 8, mailed 8/19/02. Please note: the part of rejection pertaining to biologically active fragments and percent identity has been withdrawn in view of applicant's amendments.

With respect to immunogenic fragments, applicant argues that page 55 teaches how to make antibodies to ECMP-1. This part of the specification is prophetic with

Page 3

respect to making ECMP-1 antibodies and does not specifically make one. Applicant did not address the issue of as described at page 6, section 2(3) of paper no. 8. What can the antibodies made to these immunogenic fragments be used for?

### Allowable Subject Matter

Claims 42 and 46 remain objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Application/Control Number: 09/836,561

Art Unit: 1642

Page 4

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheela J Huff whose telephone number is 703-305-7866. The examiner can normally be reached on T,Th 6am-12pm and alternate Mondays 6am-3pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Sheela J Huff Primary Examiner Art Unit 1642

sjh February 6, 2003